Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Adv Sci (Weinh) ; 11(10): e2305566, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38148412

RESUMO

Chimeric antigen receptor (CAR)-positive cell therapy, specifically with anti-CD19 CAR-T (CAR19-T) cells, achieves a high complete response during tumor treatment for hematological malignancies. Large-scale production and application of CAR-T therapy can be achieved by developing efficient and low-cost enrichment methods for CAR-T cells, expansion monitoring in vivo, and overcoming tumor escape. Here, novel CAR-specific binding aptamers (CAR-ap) to traceless sort CAR-positive cells and obtain a high positive rate of CAR19-T cells is identified. Additionally, CAR-ap-enriched CAR19-T cells exhibit similar antitumor capacity as CAR-ab (anti-CAR antibody)-enriched CAR-T cells. Moreover, CAR-ap accurately monitors the expansion of CAR19-T cells in vivo and predicts the prognosis of CAR-T treatment. Essentially, a novel class of stable CAR-ap-based bispecific circular aptamers (CAR-bc-ap) is constructed by linking CAR-ap with a tumor surface antigen (TSA): protein tyrosine kinase 7 (PTK7) binding aptamer Sgc8. These CAR-bc-aps significantly enhance antitumor cytotoxicity with a loss of target antigens by retargeting CAR-T cells to the tumor in vitro and in vivo. Overall, novel CAR-aptamers are screened for traceless enrichment, monitoring of CAR-positive cells, and overcoming tumor cell immune escape. This provides a low-cost and high-throughput approach for CAR-positive cell-based immunotherapy.


Assuntos
Receptores de Antígenos Quiméricos , Evasão Tumoral , Linfócitos T , Imunoterapia Adotiva/métodos , Imunoterapia
2.
Am J Transl Res ; 14(10): 6889-6898, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36398261

RESUMO

OBJECTIVE: Current balance training systems are designed exclusively for one particular type of training and assessment. Additionally, they comprise monotonous training programs. Therefore, patients in different stages of rehabilitation must use different balance training models from different manufacturers, resulting in high treatment cost. Furthermore, large spaces are required to accommodate the balance training machines, and doctors and physiotherapists have to learn to operate multiple machines. We aimed to design a multimodal balance training and assessment system that can accommodate the assessment and training of static, dynamic, reactive and proactive balance to satisfy individual needs. METHODS: The difficulty associated with combining static, dynamic, reactive and proactive balance training in a single system was to use radial and circumferential driving mechanisms together with a clutch mechanism, whereby circumferential and radial drivers were installed in the base of the system to drive a compound foot plate system with interchangeable springs, in order to adjust stiffness using the clutch. Based on the kinematic equation, the influence of system parameters on the change of the body's center of gravity were evaluated. The parameters included the radial offset of the driving mechanism (r), circumferential angle of rotation (θ), height of the base of the balance training system (h), horizontal distance between the body's standing center of gravity and the center of the foot plate (R), thickness of the padding mat (ΔH) and inclination angle (α). RESULTS: The difficulties associated with combining static, dynamic, reactive and proactive balance training models in a single system were solved using radial and circumferential driving mechanisms together with a clutch mechanism. The foot plate can swing back and forth within ±20° around the X-axis, swing left and right within ±20° around the Y-axis, swing diagonally within ±20°, swing 360° around the Z-axis, and adjust the height along the Z-axis. Furthermore, the inclination angle α, circumferential angle of rotation θ, and speed (dα/dt and dθ/dt) of the system can be controlled in real time. CONCLUSION: The developed balance training system is suitable for patients in different stages of rehabilitation. By providing multiple functionalities, this system can ensure high use rates, reduce costs and save space.

3.
Front Oncol ; 11: 663360, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33889549

RESUMO

B-cell acute lymphocytic leukemia (B-ALL) is a malignant blood cancer that develops in children and adults and leads to high mortality. THZ1, a covalent cyclin-dependent kinase 7 (CDK7) inhibitor, shows anti-tumor effects in various cancers by inhibiting cell proliferation and inducing apoptosis. However, whether THZ1 has an inhibitory effect on B-ALL cells and the underlying mechanism remains obscure. In this study, we showed that THZ1 arrested the cell cycle of B-ALL cells in vitro in a low concentration, while inducing the apoptosis of B-ALL cells in vitro in a high concentration by activating the apoptotic pathways. In addition, RNA-SEQ results revealed that THZ1 disrupted the cellular metabolic pathways of B-ALL cells. Moreover, THZ1 suppressed the cellular metabolism and blocked the production of cellular metabolic intermediates in B-ALL cells. Mechanistically, THZ1 inhibited the cellular metabolism of B-ALL by downregulating the expression of c-MYC-mediated metabolic enzymes. However, THZ1 treatment enhanced cell apoptosis in over-expressed c-MYC B-ALL cells, which was involved in the upregulation of p53 expression. Collectively, our data demonstrated that CDK7 inhibitor THZ1 induced the apoptosis of B-ALL cells by perturbing c-MYC-mediated cellular metabolism, thereby providing a novel treatment option for B-ALL.

4.
Front Cell Dev Biol ; 9: 641271, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33748130

RESUMO

B-cell acute lymphocytic leukemia (B-ALL), a common blood cancer in children, leads to high mortality. Cyclin-dependent kinase 9 inhibitor (CDK9i) effectively attenuates acute myeloid leukemia and chronic lymphoblastic leukemia by inducing apoptosis and inhibiting cell proliferation. However, the effect of CDK9i on B-ALL cells and the underlying mechanisms remain unclear. In this study, we showed that CDK9i induced the apoptosis of B-ALL cells in vitro by activating the apoptotic pathways. In addition, CDK9i restrained the glycolytic metabolism of B-ALL cells, and CDK9i-induced apoptosis was enhanced by co-treatment with glycolysis inhibitors. Furthermore, CDK9i restained the glycolysis of B-ALL cell lines by markedly downregulating the expression of glucose transporter type 1 (GLUT1) and the key rate-limiting enzymes of glycolysis, such as hexokinase 2 (HK2) and lactate dehydrogenase A (LDHA). Moreover, cell apoptosis was rescued in B-ALL cells with over-expressed c-Myc after treatment with CDK9i, which is involved in the enhancement of glycolytic metabolism. In summary, our findings suggest that CDK9 inhibitors induce the apoptosis of B-ALL cells by inhibiting c-Myc-mediated glycolytic metabolism, thus providing a new strategy for the treatment of B-ALL.

5.
PLoS One ; 16(3): e0248750, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33750952

RESUMO

BACKGROUND: Severe acute respiratory infection (SARI) results in a tremendous disease burden worldwide. Available research on active surveillance among hospitalized adult patients suffering from SARI in China is limited. This pilot study aimed to identify associated etiologies and describe the demographic, epidemiological and clinical profiles of hospitalized SARI patients aged over 16 years in Jinshan, Shanghai. METHODS: Active surveillance was conducted at 1 sentinel hospital in Jinshan district, Shanghai, from April 2017 to March 2018. Hospitalized SARI patients aged over 16 years old were enrolled, and nasopharyngeal swabs were collected within 24 hours of admission and tested for multiple respiratory viruses (including 18 common viruses) and Mycoplasma pneumoniae with real-time polymerase chain reaction. Demographic, epidemiological and clinical information was obtained from case report forms. RESULTS: In total, 397 SARI patients were enrolled; the median age was 68 years, and 194 (48.9%) patients were male. A total of 278 (70.0%) patients had at least one underlying chronic medical condition. The most frequent symptoms were cough (99.2%) and sputum production (88.4%). The median duration of hospitalization was 10 days. A total of 250 infection patients (63.0%) were positive for at least one pathogen, of whom 198 (49.9%) were positive for a single pathogen and 52 (13.1%) were positive for multiple pathogens. The pathogens identified most frequently were M. pneumoniae (23.9%, 95/397), followed by adenovirus (AdV) (11.6%, 46/397), influenza virus A/H3N2 (Flu A/H3N2) (11.1%, 44/397), human rhinovirus (HRhV) (8.1%, 32/397), influenza virus B/Yamagata (Flu B/Yamagata) (6.3%, 25/397), pandemic influenza virus A/H1N1 (Flu A/pH1N1) (4.0%, 16/397), parainfluenza virus (PIV) type 1 (2.0%, 8/397), human coronavirus (HCoV) type NL63 (2.0%, 8/397), HCoV 229E (1.5%, 6/397), HCoV HKU1 (1.5%, 6/397), PIV 3 (1.5%, 6/397), human metapneumovirus (HMPV) (1.5%, 6/397), PIV 4 (1.3%, 5/397), HCoV OC43 (1.0%, 4/397), influenza virus B/Victoria (Flu B/Victoria) (0.5%, 2/397), respiratory syncytial virus (RSV) type B (0.5%, 2/397), and human bocavirus (HBoV) (0.3%, 1/397). The seasonality of pathogen-confirmed SARI patients had a bimodal distribution, with the first peak in the summer and the second peak in the winter. Statistically significant differences were observed with respect to the rates of dyspnea, radiographically diagnosed pneumonia and the presence of at least one comorbidity in patients who were infected with only M. pneumoniae, AdV, HRhV, Flu A/H3N2, Flu A /pH1N1 or Flu B/Yamagata. The differences in the positivity rates of the above 6 pathogens among the different age groups were nonsignificant. CONCLUSIONS: M. pneumoniae, AdV and Flu A/H3N2 were the main pathogens detected in hospitalized SARI patients aged over 16 years old in Jinshan district, Shanghai. Our findings highlight the importance of sustained multipathogen surveillance among SARI patients in sentinel hospitals, which can provide useful information on SARI etiologies, epidemiology, and clinical characteristics.


Assuntos
Vírus de DNA/isolamento & purificação , Mycoplasma pneumoniae/isolamento & purificação , Vírus de RNA/isolamento & purificação , Infecções Respiratórias/diagnóstico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , China , Tosse/etiologia , Feminino , Glucocorticoides/uso terapêutico , Hospitais , Humanos , Masculino , Pessoa de Meia-Idade , Nasofaringe/microbiologia , Nasofaringe/virologia , Projetos Piloto , Prognóstico , Infecções Respiratórias/tratamento farmacológico , Infecções Respiratórias/microbiologia , Infecções Respiratórias/virologia , Adulto Jovem
6.
Biosci Rep ; 39(2)2019 02 28.
Artigo em Inglês | MEDLINE | ID: mdl-30429238

RESUMO

Background: Yanghe Huayan Decoction (YHD), a traditional Chinese medicine, is one of the most common complementary medicine currently used in the treatment of breast cancer (BC). It has been recently linked to suppress precancerous lesion and tumor development. The current study sought to explore the role of YHD on trans-endothelium and angiogenesis of BC. Methods: HER2+ BC cells were treated with YHD, Trastuzumab, or the combination in vitro and in vivo to compare the effects of them on trans-endothelium and angiogenesis features. The present study also investigated the potential molecular mechanism of YHD in inhibiting angiogenesis of BC. Results: YHD significantly suppressed the invasion and angiogenesis of BC cells via elevated pAkt signaling. Administration of YHD in vivo also strikingly repressed angiogenesis in tumor grafts. Conclusion: YHD could partially inhibit and reverse tumorigenesis of BC. It also could inhibit Akt activation and angiogenesis in vitro and in vivo Its effect was superior to trastuzumab. Thus it was suitable for prevention and treatment of BC.


Assuntos
Inibidores da Angiogênese/farmacologia , Neoplasias da Mama/tratamento farmacológico , Medicamentos de Ervas Chinesas/farmacologia , Neovascularização Patológica/tratamento farmacológico , Proteínas Proto-Oncogênicas c-akt/metabolismo , Inibidores da Angiogênese/administração & dosagem , Animais , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Neoplasias da Mama/irrigação sanguínea , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Linhagem Celular Tumoral , Medicamentos de Ervas Chinesas/administração & dosagem , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/patologia , Feminino , Células Endoteliais da Veia Umbilical Humana , Humanos , Camundongos Nus , Receptor ErbB-2/metabolismo , Trastuzumab/administração & dosagem , Ensaios Antitumorais Modelo de Xenoenxerto
7.
Clin Ther ; 34(11): 2212-20, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23084093

RESUMO

BACKGROUND: Sulfadoxine/pyrimethamine fixed-dose combination (FDC) tablet is the long-acting portion of the antimalaria product Artecospe(®), coblister containing artesunate tablets plus sulfadoxine/pyrimethamine FDC tablets. This study was conducted to support the efficacy and tolerability of the sulfadoxine/pyrimethamine FDC tablet in the World Health Organization's (WHO) Prequalification of Medicines Programme, as well as to obtain marketing authorization in China. OBJECTIVE: The aim of the present study was to compare the pharmacokinetic profiles between a new generic and the branded reference formulation of sulfadoxine/pyrimethamine FDC tablets, and to assess the bioequivalence of the 2 products in healthy Chinese volunteers. METHODS: This single-dose, open-label, randomized, parallel-group study was conducted in healthy Chinese male volunteers who were randomly assigned (1:1) to receive a single 1500/75-mg dose (3 × 500/25-mg tablets) of either the test or reference formulation after a 12-hour overnight fast. Seventeen blood samples were obtained over a 168-hour interval, and plasma concentrations of sulfadoxine and pyrimethamine were determined by 2 separate validated liquid chromatography-isotopic dilution mass spectrometry methods. Pharmacokinetic properties (C(max), AUC(0-72), AUC(0-168), and T(max)) were calculated and analyzed statistically. The 2 formulations were to be considered bioequivalent if 90% CIs for the log-transformed ratios of C(max) and AUC(0-72) were within the predetermined bioequivalence range of 80% to 125%, in accordance with the guidelines of WHO and China's Food and Drug Administration (FDA). Tolerability was evaluated throughout the study by vital signs, physical examinations, clinical laboratory tests, 12-lead ECGs, and subject interviews on adverse events (AEs). RESULTS: Forty-six healthy subjects completed the study. The mean values of sulfadoxine C(max) (183.07 and 165.15 mg/L), AUC(0-72) (11,036.52 and 10,536.78 mg/L/h), and AUC(0-168) (22,247.05 and 21,761.02 mg/L/h) were not significantly different between the test and reference formulations, respectively. The same was true for pyrimethamine (0.55 and 0.58 mg/L, 29.85 and 31.44 mg/L/h, and 56.18 and 59.27 mg/L/h, respectively). The 90% CIs for the log-transformed ratios of C(max), AUC(0-72), and AUC(0-168) of both sulfadoxine (105.4%-116.6%, 99.3%-110.6%, and 96.4%-108.1%) and pyrimethamine (88.8%-100.9%, 89.5%-101.0%, and 88.3%-101.6%) were within the acceptance limits for bioequivalence. A total of 7 mild AEs were reported in 7 subjects (15.2%). CONCLUSIONS: The findings from this single-dose (1500/75-mg) study suggest that the test and reference formulations of sulfadoxine/pyrimethamine FDC 500/25-mg tablet have similar pharmacokinetic profiles both in terms of rate and extent of absorption. The formulations met WHO's and China's FDA regulatory criteria for bioequivalence in these healthy Chinese volunteers under fasting conditions. Both formulations were generally well-tolerated.


Assuntos
Antimaláricos/farmacocinética , Povo Asiático , Medicamentos Genéricos/farmacocinética , Pirimetamina/farmacocinética , Sulfadoxina/farmacocinética , Administração Oral , Adolescente , Adulto , Análise de Variância , Antimaláricos/administração & dosagem , Antimaláricos/efeitos adversos , Antimaláricos/sangue , Antimaláricos/química , Química Farmacêutica , Distribuição de Qui-Quadrado , China , Cromatografia Líquida , Combinação de Medicamentos , Medicamentos Genéricos/administração & dosagem , Medicamentos Genéricos/efeitos adversos , Medicamentos Genéricos/química , Humanos , Técnicas de Diluição do Indicador , Modelos Lineares , Masculino , Espectrometria de Massas , Pessoa de Meia-Idade , Modelos Biológicos , Pirimetamina/administração & dosagem , Pirimetamina/efeitos adversos , Pirimetamina/sangue , Pirimetamina/química , Sulfadoxina/administração & dosagem , Sulfadoxina/efeitos adversos , Sulfadoxina/sangue , Sulfadoxina/química , Comprimidos , Equivalência Terapêutica , Adulto Jovem
8.
Clin Ther ; 32(5): 986-95, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20685507

RESUMO

BACKGROUND: Glimepiride is an oral sulfonylurea antihyperglycemic agent indicated for the treatment of type 2 diabetes mellitus. Although there are reports in the literature regarding the pharmacokinetic (PK) characteristics of glimepiride, few data of PK parameters are available in a Chinese population; none are available regarding a recently developed generic formulation. OBJECTIVE: To meet the requirements for marketing a new generic product in China, the study was designed to compare the PK properties and bioequivalence of 2-mg tablets of glimepiride: the newly developed generic formulation (test) and a branded formulation (reference) in healthy Chinese male volunteers. METHODS: A single-dose, randomized-sequence, open-label, 2-way crossover study was conducted in fasted healthy Chinese male volunteers. Eligible participants were randomly assigned in a 1:1 ratio to receive 1 tablet (2 mg each) of the test or reference formulation, followed by a 1-week washout period and administration of the alternate formulation. The study drugs were administered after a 10-hour overnight fast. Plasma samples were collected before study drug administration (baseline) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours after study drug administration. Concentrations in plasma of the parent glimepiride and its M1 metabolite were analyzed with a LC-MS/MS method. The formulations were considered bioequivalent if the 90% CIs for the log-transformed values were within the predetermined equivalence range (70%-143% for C(max) and 80%-125% for AUC), according to the guidelines of the State Food and Drug Administration (SFDA) of China. Tolerability was based on the recording of adverse events (AEs), monitoring vital signs, ECGs, and laboratory tests at baseline and completion of the study. RESULTS: A total of 24 healthy Chinese male volunteers were enrolled and completed the study; however, only the data from 23 subjects were included (mean [SD] age, 23.6 [2.2] years [range, 18.6-26.9 years]; weight, 64.0 [8.4] kg [range, 52.0-82.0 kg]; and height, 172.3 [5.6] cm [range, 164.0-185.0 cm) in the PK and tolerability assessments due to a violation of the protocol. For parent glimepiride, the 90% CIs for the ratios of Cmax, AUC(0-t), and AUC(0-infinity) were 93.83% to 115.19%, 90.82% to 102.29%, and 92.22% to 103.78%, respectively. For the M1 metabolite, the 90% CIs were 91.71% to 110.79%, 91.33% to 101.76%, and 89.99% to 99.85%. Both met the predetermined criteria for bioequivalence. Four AEs (17.4%) were reported: hypertriglyceridemia (2 subjects [8.7%]; 1 each receiving the test and reference formulations); increase of red blood cells in urine (1 subject [4.3%] receiving the reference formulation); and hypoglycemia (1 subject [4.3%] receiving the test formulation). The incidence of hypoglycemia was the only AE considered probably related to study drug administration; all others were considered probably not related. All AEs were transient and considered by the investigators to be mild. CONCLUSIONS: In this small study in fasted healthy Chinese male volunteers, a single 2-mg dose of the test formulation met the regulatory criteria to assume bioequivalence to the reference formulation based on the rate and extent of absorption. Both formulations were well tolerated. SFDA Registration No.: 2009L01033.


Assuntos
Hipoglicemiantes/farmacocinética , Compostos de Sulfonilureia/administração & dosagem , Compostos de Sulfonilureia/farmacocinética , Adolescente , Adulto , Área Sob a Curva , Química Farmacêutica , China , Estudos Cross-Over , Humanos , Masculino , Equivalência Terapêutica
9.
Inorg Chem ; 46(14): 5673-7, 2007 Jul 09.
Artigo em Inglês | MEDLINE | ID: mdl-17559209

RESUMO

Semiconductor CdX (X=Te, Se, S) hollow structures have been successfully prepared by using Cd(OH)Cl precursors as a sacrificial template. The hollow structures can be hollow spheres or tubes by controlling the shape of the sacrificial template. The products were characterized by X-ray diffraction, transmission electron microscopy, scanning electron microscopy, and energy-dispersive spectrometry. The obtained results showed that the hollow structures had complementary shapes and sizes of the original sacrificial templates. This is a general method for the synthesis of cadmium chalcogenide hollow structures, and the method is simpler and more practical than direct synthesis of certain hollow structures, which further widens the avenue to using those materials that have been synthesized with various shapes to fabricate specific hollow structures.

10.
Chem Commun (Camb) ; (28): 3013-5, 2006 Jul 28.
Artigo em Inglês | MEDLINE | ID: mdl-16832521

RESUMO

Cd(OH)2 nanorings were successfully fabricated from Cd(OH)2 nanoplates by ultrasonic chiselling, a unique effect of the sonochemical process that has never been reported before.

11.
Ultrason Sonochem ; 13(4): 352-8, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16011906

RESUMO

An ultrasonic-assisted solution-phase approach to tellurium bundles of nanowhiskers has been successfully established. It is a convenient and efficient process for the formation of Te nanowhiskers and their simultaneous assembly into tellurium bundles without using any templates. It was found that the transformation from Te powder to Te nanowhiskers involved the reversible disproportionation of tellurium. Sonication played a critical role for the formation of the Tellurium bundles of nanowhiskers. The bandgap of the Te nanowhiskers was calculated to be about 3.8 eV based on the UV-visible spectrum. The simplicity and rapidity of the procedure, and the newly discovered uniform morphology of the products made this synthesis promising and potential for related future applications.

12.
Langmuir ; 20(26): 11738-47, 2004 Dec 21.
Artigo em Inglês | MEDLINE | ID: mdl-15595806

RESUMO

A facile and efficient approach for the fabrication of mesoporous spherical aggregates of anatase nanocrystals is reported in this paper. Cetyltrimethylammonium bromide was used as the structure-directing agent, and the interaction between cyclohexane microdroplets and the cetyltrimethylammonium bromide self-assemblies led to the assembly of 4-5-nm-sized anatase nanocrystals into spherical aggregates with mesoporous structures. The as-prepared anatase powders exhibited high photocatalytic activity and could be effectively used as the catalyst for the room-temperature photodegradation of a variety of organic dye pollutants in aqueous media including methyl orange, bromopyrogallol red, and methylene blue.

13.
Inorg Chem ; 43(19): 5877-83, 2004 Sep 20.
Artigo em Inglês | MEDLINE | ID: mdl-15360236

RESUMO

A simple sonochemical route was developed for the crystal growth of uniform silver nanoplates and ringlike gold nanocrystals in a N,N-dimethylformamide solution. The platelike structures were generated from the selective growth on different crystal planes in the presence of poly(vinylpyrrolidone) and the ultrasonic-assisted Ostwald ripening processes. The silver nanoplates in solution served as the templates for the synthesis of ringlike gold crystals via a displacement reaction. Both the silver nanoplates and gold nanorings were highly oriented single crystals with (111) planes as the basal planes.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...